P21

A CNTF-derived peptide mimetic studied for neurogenesis, positioned as a non-peptidergic alternative to Cerebrolysin.

P21 is classified as a ciliary neurotrophic factor peptide mimetic. Its current development status is: preclinical. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks P21 because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.